Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma
-
Published:2024-08
Issue:
Volume:
Page:
-
ISSN:1590-8658
-
Container-title:Digestive and Liver Disease
-
language:en
-
Short-container-title:Digestive and Liver Disease
Author:
Tovoli FrancescoORCID, Pallotta Dante PioORCID, Vivaldi Caterina, Campani ClaudiaORCID, Federico PieraORCID, Palloni Andrea, Dalbeni AndreaORCID, Soldà CaterinaORCID, Lani LorenzoORCID, Svegliati-Baroni Gianluca, Garajova Ingrid, Ielasi LucaORCID, De Lorenzo Stefania, Granito AlessandroORCID, Stefanini BernardoORCID, Masi Gianluca, Marra FabioORCID, Lonardi Sara, Brandi Giovanni, Daniele BrunoORCID, Auriemma Alessandra, Schiadà LauraORCID, Chen Rusi, Piscaglia FabioORCID
|
|